



Roskilde, 27 February 2004

Press Release

European approval of TachoSil™ expected in May 2004

Nycomed has successfully reached a milestone in the European registration process of TachoSil™. As part of the Centralised Procedure under the European Agency for the Evaluation of Medicinal Products (EMA), the scientific assessment report is now available to Nycomed.

According to EMA, all issues from the scientific assessment panel were addressed successfully. Thus, the scientific committee has recommended that the Commission issue an EU marketing authorisation for TachoSil™. The final Commission decision is expected end of May 2004.

"With the expected approval in May, I am proud to announce that our unique new product, TachoSil™, is ready to be launched as scheduled in Europe this year," said Håkan Björklund, CEO at Nycomed.

"The launch of TachoSil™ is a cornerstone in our pan-European strategy to build closer relations with health care professionals throughout Europe," Håkan Björklund continues, "and this will further strengthen Nycomed's position on the market for hospital and specialist products."

TachoSil™ is a medicated collagen sponge coated with coagulation factors, developed to assist surgeons achieve fast and reliable bleeding control. Within minutes, it seals and protects the injured tissue to reduce the incidence of post-operative complications. TachoSil™ is safely absorbed in the body within few weeks.

For further information:

Håkan Björklund, CEO
Phone: (+45) 46 77 11 11

Christoffer Jensen, VP Communications
Phone: (+45) 46 77 11 12
Mobile: (+45) 22 43 69 44

About Nycomed

Nycomed is a European pharmaceutical company. We differentiate ourselves by our European focus and marketing strategy. Dedicated sales teams target general practitioners, hospital specialists and pharmacists. Other capabilities are product sourcing, late-stage clinical trials, registration, pricing and reimbursement negotiation and product life-cycle management.

With more than 2,800 people, mostly in marketing & sales, we cover 18 European markets including the CIS. Our products are also exported to other countries including Japan and the US.

Nycomed is a privately-owned company with 2002 revenue of €562.9 million and EBITDA (earnings before interest, taxation, depreciation and amortization) of €108.3 million.

Further information is available on: www.nycomed.com